| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8727489 | Gastroenterology | 2017 | 34 Pages |
Abstract
In a phase 2B randomized trial of patients with moderate to severe DG, relamorelin significantly reduced core symptoms of DG and overall composite score compared with placebo, accelerated GE, and was generally safe and well tolerated. ClinicalTrials.gov Identifier: NCT02357420.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Michael Camilleri, Richard W. McCallum, Jan Tack, Sharon C. Spence, Keith Gottesdiener, Fred T. Fiedorek,